Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
about
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewInflammation as a Keystone of Bone Marrow Stroma Alterations in Primary MyelofibrosisGuidelines for the management of myeloproliferative neoplasmsA multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialAlternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic reviewAssessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCTIntestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis.The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancersDiscrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary MyelofibrosisComorbidities predict worse prognosis in patients with primary myelofibrosisEfficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceCooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesAn update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.Acute duodenal ischemia and periampullary intramural hematoma after an uneventful endoscopic retrograde cholangiopancreatography in a patient with primary myelofibrosis.Molecular genetic evaluation of myeloproliferative neoplasms.Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.A comprehensive review of pacritinib in myelofibrosis.Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.Primary myelofibrosis and its targeted therapy.Management of myelofibrosis: JAK inhibition and beyond.Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosisPrognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantationDoes angiogenesis matter in primary myelofibrosis?Mutations and prognosis in primary myelofibrosis.Myelofibrosis, diffuse alveolar hemorrhage and radiation treatment.
P2860
Q24186703-66BC14F7-8FBE-43E1-BABE-D1A8D2BB47B8Q26774212-181C125B-3E0B-4C32-B457-F2DB8947E773Q26778326-D881BA8C-4B07-41D7-9565-2A0B26A3A76EQ33420095-2948305B-B46F-4C6D-9817-73E0B7C98955Q33421596-DFD5C491-5017-4F56-B097-66CC18707716Q33432637-AB4A310B-6AD7-451A-B604-9F60F44A2423Q33436416-14D4DC1F-3C51-43B5-81CF-EC00A3308176Q33436685-8766320F-482D-4257-A726-CF07452DD0E7Q33556843-FCF79FDF-7011-4822-86DC-BC05328395D2Q34137469-8E40F955-CFD6-4B5D-983C-69EBD889901EQ34840082-24072782-FA12-4716-B4C5-6F071E79D0DBQ34861658-E222C236-4B97-4562-9539-C8D54F185D0DQ35525312-3153BE8B-C4B3-4FC3-9E5A-99F32C897526Q35988523-B0E4BFD0-DBCC-4D70-B76B-699251B66795Q36364763-1B445EFA-926F-42B9-9DCA-09E340BAB635Q36817560-5BA4559E-F2AF-45C4-9ABA-5B8B5CCCFAC4Q37035925-E8E1FC65-F9F1-4EFB-8715-4582AB99E03DQ37401358-BEB792C3-490B-4D19-BEDC-C8FF343F6B8AQ37740928-51B9C4AA-8DB0-4839-A985-F648E76DE04FQ38187675-3FD81E42-41D1-40E8-B0BA-FFA8C0426EA0Q38193610-272EE4B8-87EC-48C2-BDAC-5B6C46D61F56Q38236642-EAE2BA77-B4FD-4E6A-AA1D-CF58A6B96513Q38242725-B9EFA823-0D3F-446A-B2C7-041D0CF565C9Q38403573-2CBC7FB4-B140-416D-8254-0E74C4B62E08Q38437236-619CB701-39AF-4D24-B5CC-F73A91796153Q38481945-F6A452A1-C5D9-46AD-A5A9-0A0361D0ABDEQ38567540-22B15BAC-D2E9-4840-8821-D9292C1248DAQ38586421-2A8D6A14-F09D-4A9D-9FB2-1AE33144F360Q38815464-C3024BA8-CBDC-4A08-92F4-D6CA93946B50Q38931426-E7DF45D2-4F7A-48AC-915C-52F08FDE2EA5Q39232415-5B10952C-4E53-417E-8F2F-3DDB1CAA6649Q40045490-E6778543-E9F6-42D1-9D5C-5EF23CCDCBF9Q40892218-B3A3A8F0-9C0E-4EE9-A2A5-52A8B874B527Q41519422-2FF71785-F3F9-4195-B1E0-359A552C9661Q41980585-58046A23-7789-48A4-8E32-25A0FE0EA26BQ42051491-47EE4692-019D-4AC0-8CA9-BF9CB0EFD972Q42111169-3F254627-1DBD-469E-9850-6ECEE3B2F1E0Q42723157-E8F10132-70F3-4E7F-A2E1-B44EF5409AD6Q44429606-2A1B969D-FAA3-4138-A47E-382CA3E8710CQ45090920-9EEA3B8A-A094-48F5-89D2-425704E087AF
P2860
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
@en
type
label
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
@en
prefLabel
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
@en
P2860
P356
P1476
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
@en
P2860
P304
P356
10.1002/AJH.23384
P577
2013-02-01T00:00:00Z